Mary Jo Laffler
Executive Editor, US Commercial/R&D News
Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Washington DC, USA
23+ years of experience
By Mary Jo Laffler 07 Jun 2019
In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine.
Scrip, Pink Sheet
By Mary Jo Laffler 19 Feb 2019
The data and analysis for this webinar were drawn from Pink Sheet and Scrip, both part of the Pharma Intelligence suite of intelligence solutions.
By Mary Jo Laffler 29 May 2017
Merck's PD-1 inhibitor holds the first cancer indication based on biomarkers rather than tumor location. The most significant market will be colorectal cancer.
By Mary Jo Laffler 14 Mar 2017
Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting
By Mary Jo Laffler 14 Dec 2016
Using Pharmapremia data, we analyze performance metrics for a select group of leading cancer companies to see where the sticking points are and who is winning at industry’s most important race.
Topic Cancer Strategy Company Analysis
11 Apr 2022
22 Dec 2021
02 Sep 2021
05 Jul 2021
06 Jun 2021